OpenEvidence’s $15 B valuation hinges on a niche ad-powered clinical search

OpenEvidence, a Miami-based startup founded in 2022, announced a $250 million funding round that values the company at $15 billion. The valuation follows a reported 42 million prompts processed by U.S. doctors last month, a figure that places the platform at the center of clinical decision support workflows.

How the chatbot works

The tool limits its source list to peer-reviewed journals such as the New England Journal of Medicine and the Journal of the American Medical Association. When a clinician types a query, the system retrieves relevant abstracts and guideline excerpts, then formats them into a concise answer. The architecture is a lightweight retrieval-augmented generation model that runs on commodity GPUs in the cloud, avoiding the need for large, proprietary language models.

Integration into hospitals

Mount Sinai Health System and Memorial Sloan Kettering Cancer Center have embedded OpenEvidence into their electronic health record (EHR) systems. NYU Langone’s chief health informatics officer noted that clinicians were already using the tool as an independent resource before the hospital formalized a partnership. The integration focuses on secure, auditable usage and limits the chatbot to evidence-based sources.

Ad-powered revenue model

OpenEvidence’s revenue comes from advertising. The company booked $100 million in ad commitments for 2025 and projects $400-$500 million in ad revenue by the end of 2026. The ads appear in the chat interface and are tailored to medical specialties. The model allows the company to keep the service free for clinicians while monetizing the large user base.

Market context

The medical software market has been slow to adopt generative AI. Dutch IT group Wolters Kluwer released an AI version of its UpToDate tool in October 2025, nearly two years after OpenEvidence entered the space. OpenEvidence’s focus on a curated source list and tight integration with EHRs gave it a head start.

Competition and scrutiny

Large AI firms such as OpenAI and Anthropic are expanding into healthcare, raising concerns about accuracy and patient safety. Researchers question the reliability of OpenEvidence’s answers, especially as clinicians rely on the tool to shape treatment plans. The company’s rapid growth has attracted nearly $1 billion in investment from Andreessen Horowitz, Blackstone, Thrive Capital, and Sequoia.

Future directions

OpenEvidence is extending its reach into ambient documentation, enabling note-taking during patient encounters. The company also plans to deepen its integration with specialty clinics, leveraging its existing relationships to broaden adoption.

OpenEvidence’s impact on clinical workflow

Interviews with eight senior physicians suggest the chatbot reduces time spent searching literature. The tool’s focus on peer-reviewed content aims to mitigate misinformation, but the reliance on a limited source list may omit emerging studies.

OpenEvidence’s next milestones

The company aims to secure additional ad revenue and expand its partner network. It must also address regulatory scrutiny over the accuracy of AI-generated medical advice.

OpenEvidence’s place in the broader AI ecosystem

The startup’s success illustrates a niche where ad-supported AI can thrive without the need for massive language models. Its model contrasts with the subscription-based approach of larger vendors and highlights the potential for targeted, evidence-driven AI tools in specialized domains.

FAQ snippets

What does OpenEvidence do?

OpenEvidence offers a chatbot that searches peer-reviewed journals and guidelines to aid clinicians in diagnosis and treatment.

How is OpenEvidence monetized?

Through advertising revenue, with $100 million in ad buys booked for 2025 and projected $400-$500 million by 2026.

Related coverage

Explore more on this topic